This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Sanofi (China) Investment Co., Ltd. Shanghai Branch, Shanghai Jiao Tong University. Active years: 2017.
Company Filing History:
1 out of 1 
1 out of 410 
Years Active: 2017
Title: Innovations of Zhenghua Wu in Monoclonal Antibody Development.
Introduction
Zhenghua Wu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on innovative solutions for cancer treatment.
Latest Patents
Zhenghua Wu holds a patent for an AGR2 blocking antibody and its use. The patent discloses a humanized monoclonal antibody designed to block AGR2. It also includes a pharmaceutical composition containing the antibody and methods for its preparation. Furthermore, the patent outlines the use of this antibody in inhibiting tumor growth and metastasis.
Career Highlights
Throughout his career, Zhenghua Wu has worked with notable organizations, including Sanofi (China) Investment Co., Ltd., Shanghai Branch, and Shanghai Jiaotong University. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.
Collaborations
Zhenghua Wu has collaborated with esteemed colleagues, including Dawei Li and Hao Guo. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Zhenghua Wu's contributions to monoclonal antibody development represent a significant advancement in cancer treatment. His innovative work continues to impact the field of biotechnology positively.